Related Experiment Video
Updated: Mar 17, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
1.0K
Statin Use in Prostate Cancer: An Update
Melissa A Babcook1, Aditya Joshi2, Jeniece A Montellano3
1Department of Urology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Department of Nutrition, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Nutrition and Metabolic Insights
|July 22, 2016
Summary
Statins, or 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, may offer benefits for prostate cancer prevention and treatment. Further research, including clinical trials, is recommended to confirm these findings.
Area of Science:
- Oncology
- Pharmacology
- Cardiovascular Medicine
Background:
- Statins (3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are widely used for hypercholesterolemia and cardiovascular disease.
- Emerging evidence suggests a potential role for statins in prostate cancer management.
Purpose of the Study:
- To systematically review and discuss the current clinical literature on the relationship between statin use and prostate cancer.
- To identify research gaps and recommend future study directions.
Main Methods:
- Systematic literature search using keywords "statin and prostate cancer" in PubMed, Web of Science, and Cochrane Library (2004-2015).
- Inclusion of meta-analyses, patient databases, observational studies, and case-control studies.
- Focus on studies addressing statin use, prostate cancer pathology, and recurrence.
Main Results:
- Accumulating clinical evidence, though premature, indicates potential benefits of statins in preventing and/or treating prostate cancer.
- Studies reviewed include secondary endpoints from cardiovascular trials, database analyses, and observational research.
Conclusions:
- Further investigation with randomized, placebo-controlled clinical trials is warranted to confirm the efficacy of statins in prostate cancer.
- Preclinical studies are needed to elucidate mechanisms and compare lipophilic versus hydrophilic statin effectiveness in prostate cancer.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:15Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
588
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
691
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
691
01:26Atherosclerosis III: Management
567
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567